Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety Disorder

Toby Wise, Fiona Patrick, Nicholas Meyer, Ndaba Mazibuko, Alice E. Oates, Anne H.M. van der Bijl, Philippe Danjou, Susan M. O’Connor, Elizabeth Doolin, Caroline Wooldridge, Deborah Rathjen, Christine Macare, Steven C.R. Williams, Adam Perkins, and Allan H. Young

ABSTRACT

BACKGROUND: Generalized anxiety disorder is associated with hyperactivity in the amygdala-prefrontal networks, and normalization of this aberrant function is thought to be critical for successful treatment. Preclinical evidence implicates cholinergic neurotransmission in the function of these systems and suggests that cholinergic modulation may have anxiolytic effects. However, the effects of cholinergic modulators on the function of anxiety-related networks in humans have not been investigated.

METHODS: We administered a novel α7 nicotinic acetylcholine receptor–negative allosteric modulator, BNC210, to 24 individuals (3 male subjects) with generalized anxiety disorder and assessed its effects on neural responses to fearful face stimuli.

RESULTS: BNC210 reduced amygdala reactivity to fearful faces relative to placebo and similarly to lorazepam and also reduced connectivity between the amygdala and the anterior cingulate cortex, a network involved in regulating anxious responses to aversive stimuli.

CONCLUSIONS: These results demonstrate for the first time that the function of disorder-relevant neural circuits in generalized anxiety disorder can be beneficially altered through modulation of cholinergic neurotransmission and suggest potential for this system as a novel target for anxiolytic pharmacotherapy.

Keywords: Amygdala, Anterior cingulate cortex, Cholinergic modulation, Generalized anxiety disorder, fMRI, Pharmacotherapy

https://doi.org/10.1016/j.biopsych.2019.12.013
these effects; rodent studies have demonstrated increases in anxiety arising from increased nAChR activity (16), implicating nAChRs specifically in anxious behavior. In particular, z7 nAChR antagonist infusion has been linked to anxiolytic behavior (17), and the high concentration of these receptors in the amygdala suggests that the effects of nAChR modulation may be mediated by changes in amygdala function (18).

Investigation of alternative anxiolytic compounds is particularly important in the context of the limitations of currently available pharmacological interventions for anxiety. For example, physical dependence, development of tolerance, and issues with withdrawal occur when benzodiazepines are used long term (19,20), while serotonin/noradrenaline reuptake inhibitors may take weeks to develop their anxiolytic effects and involve unpleasant side effects that can impact compliance (2). However, there is no research to date investigating the role of cholinergic neurotransmission in the function of networks associated with anxiety disorders in humans, and it is unclear whether modulation of cholinergic signaling might beneficially alter pathological activity in these networks. We tested this by administering a novel z7 nAChR-negative allosteric modulator, BNC210, to individuals with GAD.

BNC210 is a selective, negative allosteric modulator of the z7 nAChR in development by Bionomics Limited (Thebarton, Australia) for the treatment of anxiety, trauma, and stressor-related disorders. It inhibits rat and human z7 nAChR currents (in stably transfected cell lines) induced by acetylcholine, nicotine, choline, and the z7-specific agonist PNU-282987, with IC50 values in the range of 1.2 to 3 μM. BNC210 does not displace alpha-bungarotoxin binding, and its inhibitory effects are not influenced by the concentration of acetylcholine used (EC20 or EC80), providing evidence that the modulation is via an allosteric site. It does not show any activity in binding, fluorescent, or electrophysiology assays at other members of the cys-loop ligand-gated ion channel family and has been screened at over 700 targets in assays ranging from binding to functional (in all modes including allosteric) (21).

In preclinical models, the anxiolytic profile of BNC210 is compelling and has been observed at low doses in several rodent species and models of anxiety (22). In addition to acute anxiolytic promise in nonclinical models of anxiety, BNC210 has demonstrated safety in human studies and lack of side effects including sedation, impaired motor coordination, cognitive impairment, development of tolerance, and physical dependence, offering several advantages over benzodiazepines and antidepressants. Effects of BNC210 on amygdala reactivity to fearful faces, a well-replicated biomarker for anxiety disorders that is known to be ameliorated by existing treatments, were assessed and validated against placebo and lorazepam (a positive control). We hypothesized that BNC210 would reduce amygdala responses to fearful faces and conducted follow-up exploratory analyses examining whether such effects were associated with altered connectivity in a wider, anxiety-related, amygdala-anterior cingulate cortex network.

METHODS AND MATERIALS

Participants

In all, 24 volunteers with GAD participated in the study. Participants were recruited via online advertisements that contained a web link for a 50-item online version of the Trait Self-Description Inventory, a nonclinical Big Five personality questionnaire (23). Individuals scoring ≥ 1 SD than the population mean on neuroticism were invited to undergo telephone screening and if eligible were invited to a formal psychiatric and physical health screening session [further explanation of this method can be seen in Patrick et al. (23)]. All participants provided informed consent, and the study was approved by the London-Chelsea Research Ethics Committee.

GAD diagnosis was established in accordance with DSM-IV, using the Mini-International Neuropsychiatric Interview (24), administered by clinicians trained in the study protocol. Participants were excluded on the basis of a score >15 on the Montgomery–Åsberg Depression Rating Scale (25); any significant cardiovascular, gastrointestinal, hepatic, renal, respiratory, endocrine, immunologic, or hematological disease; use of any prescription or over-the-counter drug within less than 5 times the elimination half-life preceding dosing (with the exception of contraceptive medications); and use of any prescription drug that is a potential cytochrome P450 3A4 inducer within 30 days prior to dosing. Participants were all right-handed. Participants were to have refrained from smoking within the preceding 3 months and were breath-tested at each visit to ensure compliance. Participants were all currently treatment free (including psychological therapies). Participants did not hold a prescription for benzodiazepines and were drug screened at each visit.

Experimental Procedure

This study constituted a 4-way crossover, double-blind, randomized controlled trial. The novel compound, BNC210, was orally administered as a liquid suspension at 2 strengths (a low dose of 300 mg and a high dose of 2000 mg). BNC210 was previously investigated in 4 clinical trials (at single doses ranging from 5 to 2000 mg) with 84 subjects being exposed to BNC210 at 2000 mg (oral suspension, fed). The maximum tolerated dose has not been reached in animal toxicology studies or in humans, and no safety concerns have been identified at any dose. Maximum exposure from single doses has been achieved with the 2000-mg liquid suspension formulation. Based on anxiolytic activity in animal models, 300 mg is the anticipated clinically effective human dose; however, the highest dose of 2000 mg was also used to maximize the opportunity of achieving high enough exposure to detect a response in the brain. Exposure is not linear between the 300-mg and 2000-mg doses; the increase is approximately 4-fold (protocol BNC210.002 listed on http://www.anzctr.org.au). Capsule lorazepam at 1.5 mg was orally administered as the active control compound [doses of 1.5–3 mg have been recommended as anxiolytic in patient populations, with greater than 2 mg suggested as sedative or causing substantial psychomotor slowing (26,27)]. Placebo was presented as either a liquid or a capsule, depending on which medication it was replacing (Figure 1). Following inclusion in the trial, participants attended 4 dosing sessions, receiving 1 of the 4 interventions (high-dose BNC210, low-dose BNC210, lorazepam, or placebo) at each visit in a randomized order. These were spaced with a minimum of 5 days between dosing to allow for pharmacological
washout. Before each dosing, participants were given a medical health check and a standardized, high-fat breakfast. They were also instructed to avoid all caffeine-containing products for 12 hours before the visit.

As the absorption rates of BNC210 and lorazepam differ, with time taken to reach peak concentration occurring at approximately 5 hours and 2 hours, respectively, the dosing schedule incorporated two dose administrations per visit, with one always being a placebo, to maintain the blind for both participants and researchers. For the placebo condition, subjects were administered two placebos at 5 and 2 hours before testing, in line with the administration times for the active drugs.

Symptom Measures
At enrollment, participants completed the Big Five personality questionnaire and the Hamilton Anxiety Rating Scale (HAM-A) (28). Self-report anxiety data were also recorded at 3 time points—before first drug administration, immediately before scanning, and following completion of fMRI acquisition—using the state subscale of the State-Trait Anxiety Inventory (29).

fMRI Acquisition
fMRI was performed 5 hours after first drug/placebo administration. Data were acquired on a MR750 3-Tesla scanner with a 12-channel head coil (GE Healthcare, Chicago, IL); 180 volumes were acquired per functional run using a T2*-weighted echo-planar imaging sequence (repetition time = 2000 ms, echo time = 30 ms, field of view = 22.1 cm, flip angle = 75°, 41 slices, resolution = 3.3 mm³), with 4 initial volumes discarded to allow for magnetization equilibration effects. Cardiac signals were recorded with a plethysmograph, while respiration was measured using a respiratory belt. A high-resolution T1-weighted image was also acquired (repetition time = 7.31 ms, echo time = 3.02 ms, 256 × 256 matrix, 196 slices, voxel size = 1.2 × 1.05 × 1.05 mm).

Emotional Faces Task
We used an emotional faces processing task previously shown to activate the amygdala (30,31). Faces of three emotions (fearful, happy, sad) at two intensities (medium and high) taken from the Ekman emotional faces set (32) were displayed for 2 seconds each, interleaved with neutral faces. Each emotion was shown in a separate run, each lasting approximately 6 minutes. To encourage implicit processing of the emotional faces in the task (33), participants reported the gender of the faces using a button box with their right hand. This has been shown to produce robust effects and to detect disorder-related alterations in emotion processing (34,35). Here, we focused on the fearful face condition given our hypotheses regarding threat-related processing; however, results for the other emotions are provided in Supplemental Table S2.

fMRI Preprocessing
Data were preprocessed with custom Nipype (http://nipy.org/nipype/) scripts, using tools from SPM12 (http://www.fil.ion.ucl.ac.uk/spm) and custom code. Images were initially realigned to the first image of the first session, slice timing corrected, and co-registered to the high-resolution T1 image from the first session. Segmentation and normalization were performed on the T1 image, and deformation fields were then used to normalize the functional images to MNI space before smoothing with a 6-mm full width at half maximum kernel. Subjects exhibiting substantial translation of over 1 voxel (3 mm) were removed from further analyses to prevent contamination by gross head movement. Volumes exhibiting high levels of motion were identified using ArtifactDetect, implemented in Nipype, based on realignment parameters and volume-to-volume signal intensity changes. Physiological signals were processed using custom scripts implementing the RETROICOR algorithm (36) to produce cardiac and respiratory regressors for use in first-level analyses.

Statistical Analysis
Data were analyzed using SPM12. First-level models were formed including regressors for each emotion at each level (neutral, medium, high), along with 6 motion parameters generated during realignment, and physiological regressors generated by the RETROICOR procedure. We also included motion “scrubbing” regressors to exclude volumes exhibiting high motion from the analysis, a procedure that has been demonstrated to increase statistical power in fMRI analysis and reduce confounding effects of motion (37).

The contrast of interest for these analyses was formed by comparing the medium- and high-intensity fear emotions.
against fixation (modeled as an implicit baseline condition). This approach was chosen in favor of a contrast against neutral faces owing to substantial evidence indicating that anxious individuals perceive affectively neutral expressions as negative (38), suggesting that neutral faces would not represent true affective neutrality.

We tested for drug effects using paired t tests against placebo in SPM12, with head motion, measured as the total distance traveled, as a covariate. In addition, F tests across all drug conditions are reported in Supplemental Table S2. We used a region of interest (ROI) approach with the MarsBaR toolbox (www.marsbar.sourceforge.net) to compare mean activity in our a priori amygdala ROI while viewing fearful faces between drug conditions, correcting for multiple comparisons across the two hemispheres using false discovery rate (FDR) correction. To maximize our power to detect changes in fear-relevant processing, the chosen ROI was derived from the Neurosynth (www.neurosynth.org) map for the term “fear” to identify regions most associated with responses to fear. The conjunction of this map and the Automated Anatomical Labelling atlas (39) amygdala regions was used to create ROIs. All ROI analyses were FDR corrected for multiple comparisons across the two hemispheres.

We also performed exploratory whole-brain analyses to identify other effects on reactivity to fearful faces. These analyses used a cluster-defining threshold of \( p < .001 \) and a clusterwise threshold of \( p < .05 \), FDR corrected for multiple comparisons across the whole brain.

**Functional Connectivity**

To assess whether drug effects on amygdala reactivity were part of a wider response within anxiety-relevant amygdala-prefrontal networks, we performed generalized psychophysiological interaction analyses for drug conditions showing significant effects on amygdala reactivity using the generalized psychophysiological interaction toolbox (https://www.nitrc.org/projects/gppi). For each participant, two analyses were performed with the extracted first eigenvariate time courses of the left and right amygdala ROIs, using the same fear versus baseline contrast as the main analyses. Group-level effects were examined using a \( 2 \times 2 \) analysis of variance with seed hemisphere and drug as factors and head motion as a covariate. To test for effects of the drug, accounting for hemispheric differences, we conducted a t test on the main effect of drug condition. Given a large body of evidence showing modulatory effects of the anterior cingulate cortex on amygdala activity (10) and associations between connectivity in this network and anxiety (11,12), we used an ROI approach with masks taken from the Automated Anatomical Labelling anterior and midcingulate regions. Results were thresholded with a voxelwise threshold of \( p < .001 \) uncorrected and a clusterwise threshold of \( p < .05 \), FDR corrected within the a priori selected ROI. We also report whole-brain results for completeness.

**RESULTS**

**Participants**

Three subjects were removed from analyses owing to excessive motion. Table 1 shows the average age and HAM-A and neuroticism personality scores for the sample; HAM-A scores of 17 sit within the mild to moderate range of clinical anxiety (40). None of the participants met the Mini-International Neuropsychiatric Interview criteria for major depressive disorder or scored over 15 on the Montgomery–Åsberg Depression Rating Scale as per the eligibility criteria. The final sample included 21 individuals (19 female, 2 male). There was no significant difference between genders in HAM-A scores.

**Behavioral Results**

Participants demonstrated high accuracy on the gender discrimination task (mean = 87.8%, SD = 4.4%). None of the drug conditions differed significantly from placebo in accuracy (lowest \( p = .14 \)); however, reaction times were significantly slower than placebo in the lorazepam condition \( t_{20} = 5.53, p < .001, d = 1.21 \), suggesting task vigilance but motor slowing in line with known effects of benzodiazepines.

**Motion Differences Between Drug Conditions**

Table 1. Age at Enrollment and Hamilton Anxiety Rating Scale (HAM-A) and Neuroticism Scores at Screening

| Measure         | Mean  | SD  |
|-----------------|-------|-----|
| Age, Years      | 28.4  | 6.5 |
| HAM-A Score     | 17.8  | 9.7 |
| Neuroticism Score | 53.4  | 6.6 |

There were no differences in total distance traveled between drug conditions, although the BNC210 high-dose condition showed a trend toward a reduction in movement (lorazepam: \( t_{20} = -1.04, p = .31 \); BNC210 low dose: \( t_{20} = 0.18, p = .86 \); BNC210 high dose: \( t_{20} = -1.80, p = .09 \)). Nonetheless, to remove motion-related variance, motion was included as a covariate in further analyses.

**Viewing Fearful Faces Increases Amygdala Activity**

To assess the effects of the emotion manipulation in the absence of drug effects and confirm that the manipulation was activating the amygdala as expected, we explored the effects of viewing fearful faces in the placebo condition. As expected, results revealed a significant response to fearful faces in both left \( t_{20} = 5.32, p < .001 \) and right \( t_{20} = 4.51, p < .001 \) amygdala. Whole-brain analysis revealed several other regions responding to fearful faces, which are described in Supplemental Table S1. There were no significant correlations between amygdala reactivity to fearful faces and trait anxiety, state anxiety before scanning, or neuroticism.

**BNC210 Reduces Amygdala Reactivity to Fearful Faces**

Relative to placebo, the low dose of BNC210 significantly reduced left \( t_{20} = 2.78, p = .011 \) and right \( t_{20} = 3.07, p = .006 \) amygdala reactivity (Figure 2A, B). Lorazepam significantly reduced activity in the right \( t_{19} = 2.21, p = .047 \) but not left \( t_{19} = 1.78, p = .09 \) amygdala. There was no difference between placebo and BNC210 high dose \( p = .33 \), both left and right amygdala. Whole-brain exploratory analyses showed no effect of either drug in other regions on activity while viewing fearful faces.
BNC210 Decreases Amygdala-Anterior Cingulate Functional Connectivity

To investigate whether reductions in amygdala reactivity were associated with reduced connectivity in a larger anxiety-relevant network, we performed generalized psychophysiological interaction analyses on connectivity between the amygdala and anterior cingulate. This revealed a reduction in connectivity between the amygdala and anterior cingulate cortex while viewing fearful faces under the BNC210 low dose (peak = $212, 41, 14; t = 4.22; p = .012, FDR corrected) (Figure 3A, B). This remained significant at the whole-brain level (peak = $9, 41, 20; t = 4.24; p = .018, FDR corrected); however, no other significant clusters emerged. There were no differences in connectivity between placebo and lorazepam conditions, and connectivity strength in the placebo condition did not correlate significantly with state anxiety before scanning or neuroticism.

DISCUSSION

We investigated the effects of a novel $\alpha$7 nAChR-negative allosteric modulator, BNC210, on anxiety-relevant neural circuits in individuals with GAD using fMRI. Our results demonstrate that a low dose of BNC210 reduces amygdala responses to fearful faces and reduces task-related anterior-cingulate functional connectivity in a sample of individuals with GAD, suggesting for the first time that cholinergic neurotransmission plays a critical role in the function of these networks and that drugs targeting this system may be beneficial in the treatment of anxiety disorders.

Amygdala hyperactivity to threat-related stimuli is a well-described marker of anxiety (4,5), and drugs targeting both GABAergic and serotonergic systems have been shown to reduce amygdala activity to these stimuli (6,41), suggesting that normalization of amygdala response may be critical for the therapeutic effects of anxiolytic medication. This effect has also been shown in response to no pharmacological frontline interventions, such as cognitive behavioral therapy (42), suggesting that interventions leading to reduction in amygdala hyperactivity hold promise. Our results indicate that negative allosteric modulation of $\alpha$7 nAChR by BNC210 reduces amygdala reactivity in line with approved therapeutic interventions through its actions on cholinergic neurotransmission.

We also showed that BNC210 reduces amygdala–anterior cingulate functional connectivity, which is elevated in clinical anxiety (12) and is implicated in anxious responses to aversive stimuli (11,43). Connectivity within this network is affected by manipulations of serotonergic neurotransmission (44), suggesting that normalization of hyperactivity in this network may mediate the actions of serotonin-targeting pharmacotherapy on symptoms of anxiety. Our results demonstrate that negative allosteric modulation of the $\alpha$7 nAChR receptor, and hence reduced action of acetylcholine at synapses expressing these receptors, reduces connectivity between the amygdala and anterior cingulate cortex. This indicates that cholinergic neurotransmission plays an important role in the functioning of this network and provides more evidence for the potential of cholinergic modulation in modulating anxiety-relevant neurocircuitry.

Lorazepam significantly reduced right but not left amygdala reactivity to fearful faces. It should be noted that the relatively modest effects of lorazepam compared with previous work may result from the dose of the drug used here. We purposely selected a moderate dose to prevent unblinding by the sedative effects of lorazepam at higher doses, and this may have diminished its effects at the neural level. The half-life of lorazepam is around 60 to 120 minutes (6); as our task was administered at 120 minutes from ingestion of lorazepam, this may have also had an effect.

The effects of BNC210 may be explained by suppressive action on glutamatergic interneurons in the basolateral...
amygdala. The amygdala is subject to both excitatory and inhibitory regulation from glutamatergic and GABAergic interneurons, respectively, and the action of these interneurons is dependent on cholinergic activity at $\alpha_7$ receptors (45). Although preclinical evidence suggests that $\alpha_7$ stimulation increases inhibitory activity in interneurons of the amygdala, potentially through upregulation of GABAergic inhibitory interneurons (45) resulting in reduced responses to direct stimulation, clinical anxiety may be associated with relatively increased excitatory glutamatergic interneuron activity, in which case BNC210 increases inhibitory activity in interneurons of the amygdala, in line with previous animal work (16). This study has several strengths. First, the double-blind, double-dummy crossover design reduced expectation effects and minimized between-subject variability in responses. Additionally, the use of lorazepam as a positive control treatment enabled us to ensure that negative results were not due to an insensitivity of the design to pharmacological manipulations of emotion processing, as lorazepam has previously been shown to reduce amygdala reactivity to threat. A further strength of this work was the use of physiological and motion-related denoising methods in the fMRI preprocessing and analysis to maximize power and to reduce influence of confounding factors.

The absence of a healthy control group is a limitation of this study, although if BNC210 is indeed normalizing anxiety-related hyperresponsive neurocircuitry, it is possible that no effect would have been seen in healthy individuals. Although patients were excluded if their Montgomery–Åsberg Depression Rating Scale score was $>15$, subjects did exhibit some symptoms of depression as expected owing to the high level of comorbidity between these conditions; however, none of the participants reached a clinically diagnostic level, and depressive symptoms are thus not expected to affect findings. Indeed, the presence of symptoms related to depression suggests that the present sample is in line with common presentations of GAD. Length of GAD symptomatic experience (beyond the 6 months specified by the Mini-International Neuropsychiatric Interview) was not recorded, and in accordance with the requirements of the trial, participants were currently treatment free; however, all the participants met diagnostic criteria for GAD as determined by structured interview and experienced psychiatrists. There is some evidence suggesting that anxiolytics may have altered effect depending on menstrual cycle stage (46), although this is not unanimously agreed (47); no information regarding this was collected, so potential effects cannot be commented on here.

Finally, we found no relationship between amygdala reactivity or amygdala-anterior cingulate connectivity with self-report measures of anxiety or neuroticism. However, as all participants in the study had a highly anxious personality profile, this part of the analysis is affected by range restriction, especially as state anxiety scores are typically highly positively correlated with trait anxiety scores (e.g., $r = .63$) (48); hence, maintaining the high state anxiety score is, to a degree, recapitulating the participants’ personality (trait) profile. Future work could explore the use of in-scanner visual analog scales to achieve a more nuanced measure of subjective anxiety with closer temporal proximity to task. This study provides a basis for future work on cholinergic systems in anxiety and raises several interesting questions. Firstly, the exact mechanisms through which modulation of cholinergic neurotransmission leads to changes in amygdala reactivity remain unclear, although existing preclinical work suggests directions for future work in this area. Secondly, it is not clear how cholinergic modulation affects amygdala-anterior cingulate connectivity, particularly whether this is due to top-down effects of BNC210 in the anterior cingulate cortex or to bottom-up effects at the amygdala that drive anterior cingulate activity. This is a challenging question to address in human fMRI, which animal work could help to answer. It is also of interest that only the low dose of BNC210 had a significant effect on amygdala reactivity, and this raises the possibility of the dose-response relationship being U-shaped rather than linear. The specificity of BNC210 for the $\alpha_7$ nAChR has been explored in
prior studies (21,22), identifying no “off-target” effects that might otherwise explain these data. This supports the suggestion that the findings may represent homeostatic rebalancing; z7 nAChR is expressed on both GABAergic and glutamatergic interneurons in the amygdala (and hippocampus) (45), indicating that it may have a role in maintaining the inhibitory/excitatory balance in these locations. Finally, it remains to be seen whether cholinergic modulation through agents such as BNC210 is effective in treating symptoms of clinical anxiety, and future studies will investigate this.

In conclusion, our study is the first to demonstrate that modulation of cholinergic neurotransmission has a normalizing effect on exaggerated threat-related amygdala function in GAD, suggesting a new target for pharmacological treatment for anxiety disorders.

ACKNOWLEDGMENTS AND DISCLOSURES

The study was funded by Biomics Ltd (to AHY and AMP). AHY, SCRW, and AMP are supported by the National Institute for Health Research Biomedical Research Centre at the South London and Maudsley National Health Service Foundation Trust and King’s College London. This report represents independent research funded by the National Institute for Health Research Biomedical Research Centre and South London and Maudsley National Health Service Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research, or Department of Health. TW is funded by a Welcome Trust Sir Henry Wellcome fellowship.

AHY and SCRW are members of the Biomics Scientific Advisory Board. SMO and ED are employed by Biomics Ltd. All other authors report no biomedical financial interests or potential conflicts of interest.

EU Clinical Trials Register: A Randomized, Double-Blinded, Placebo and Lorazepam-Controlled, Four-Way Crossover, Phase II Study to Evaluate the Effects of Single Oral Administration of BNC210 on Brain Activity Changes Captured by Functional Magnetic Resonance Imaging in Adults With Generalized Anxiety Disorder; https://www.clinicaltrialsregister.eu ctr-search/trial/2014-004937-15/GB; BNC210.006.

ARTICLE INFORMATION

From the Department of Psychological Medicine (TW, FP, CM, AP, AHY), Department of Neuroimaging (FP, NMa, CW, SCRW), and Department of Psychiatry Studies (NMe), Institute of Psychiatry, Psychology & Neurosciences, King’s College London; Wellcome Trust Centre for Neuroimaging (TW), University College London; Max Planck UCL Centre for Computational Psychiatry and Ageing Research (TW); National Institute for Health Research Biomedical Research Centre (SCRW, AP, AHY); South London; and Maudsley NHS Foundation Trust (AEO), London, UK; Department of Humanities and Social Sciences (TW), California Institute of Technology, Pasadena, California; Faculty of Social and Behavioural Sciences (AHMvdB), University of Leiden, Leiden, Netherlands; Biotrial (PD), Paris, France; Biometrics Ltd (SMO, ED), Thebarton, Australia; and BiOasis Technologies Inc. (DF), Guilford, Connecticut.

TW and FP contributed equally to this work.

AP and AHY contributed equally to this work.

Address correspondence to Toby Wise, Ph.D., Max Planck UCL Centre for Computational Psychiatry and Ageing Research, London WC1B 5EH, United Kingdom; E-mail: t.wise@ucl.ac.uk.

Received May 21, 2019; revised Nov 25, 2019; accepted Dec 11, 2019.

Supplementary material cited in this article is available online at https://doi.org/10.1016/j.biopsych.2019.12.013.

REFERENCES

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005): Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:593–602.
2. Katzman MA (2012): Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 23:103–120.
3. Schweizer E, Rickeis K (1998): Benzodiazepine dependence and withdrawal: A review of the syndrome and its clinical management. Acta Psychiatr Scand 98:95–101.
4. Etkin A, Prater KE, Hoett F, Menon V, Schatzberg AF (2010): Failure of anterior cingulate activation and connectivity with the amygdala during implicit regulation of emotional processing in generalized anxiety disorder. Am J Psychiatry 167:545–554.
5. Nitschke JB, Sarinopoulos I, Oathes DJ, Johnstone T, Whalen PJ, Davidson RJ, Kalin NH (2009): Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry 166:302–310.
6. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB (2005): Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 62:282–288.
7. Anderson IM, Del-Ben CM, Mickie S, Richardson P, Williams SR, Elliott R, Long Beach, Deakin JF (2007): Citalopram modulation of neuronal responses to aversive face emotions: A functional MRI study. Neuroreport 18:1351.
8. Labusagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, et al. (2010): Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 35:2403–2413.
9. Faria V, Appel L, Čhe F, Linnman C, Pisciotta A, Frans Ó., et al. (2012): Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder. Neuropsychopharmacology 37:2222–2232.
10. Etkin A, Egner T, Peraza DM, Kandel ER, Hirsch J (2006): Resolving the adaptive threat bias in anxiety: Amygdala–dorsomedial prefrontal cortex coupling and aversive amplification. Neuroimage 60:523–529.
11. Robinson OJ, Charney DR, Overstreet C, Vytal K, Grillon C (2012): The adaptive threat bias in anxiety: Amygdala–dorsomedial prefrontal cortex coupling and aversive amplification. Neuroimage 101:1403–1412.
12. Robinson OJ, Krimsy M, Lieberman L, Allen P, Vytal K, Grillon C (2014): The dorsal medial prefrontal (anterior cingulate) cortex–amygdala aversive amplification circuit in unmedicated generalised and social anxiety disorders: An observational study. Lancet Psychiatry 1:294–302.
13. Borsook D, Becerra L, Hargreaves R (2006): A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 5:411–425.
14. Sienkiewicz-Jarosz H, Czlonkowska AI, Siemiatkowski M, Maciejak P, Szyndler J, Planik A (2000): The effects of phystostigmine and cholinergic receptor ligands on novelty-induced neophobia. J Neural Transm (Vienna) 107:1403–1412.
15. Seguela P, Wadiche J, Dani JA, Patrick JW (1993): Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13:598–604.
16. Janssen K, Roser P, Hoffmann K (2015): The problems of long-term treatment with benzodiazepines and related substances. Dtsch Arztebl Int 112:1–7.
17. Medicines COTRO (1980): Systematic review of the benzodiazepines: Guidelines for data sheets on diazepam, chlordiazepoxide,
Cholinergic Modulation in Clinical Anxiety

medazepam, lorazeepam, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Br Med J 280:910–912.

21. O’Connor SM, Grishin AA, Poraid E, Huyard B, Coles C, Kolev Y, et al. (2014): The novel anxiolytic compound BNC210 is a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor. Washington DC: Presented at Neuroscience 2014, November 15, 2014.

22. O’Connor S, Andriambelison E, Huyard B, Wagner S, Sleebs B, Bui C, et al. (2008): BNC210 is a novel, fast-acting compound with potent anxiolytic activity and no side effects. Eur Neuropsychopharmacol 18: S495–S495.

23. Patrick F, Young AH, Williams SC, Perkins AM (2018): Prescreening clinical trial volunteers using an online personality questionnaire. Neuropsychiatr Dis Treat 14:2297–2303.

24. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Harnett Sheehan K, et al. (1997): The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI. Eur Psychiatry 12:224–231.

25. Montgomery SA, Asberg M (1979): A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.

26. Collard J (1971): Initial psychopharmacological study of lorazepam (Wy 4036). Arzneimittelforschung 21:1091–1095.

27. Hege SG, Ellwood EH Jr, Wilson WH, Helligers CAM, Graham SM (1997): Psychomotor effects of the anxiolytic abecarnil: A comparison with lorazepam. Psychopharmacology (Berl) 131:101–107.

28. Bruss GS, Gruenberg AM, Goldstein RD, Barber JP (1994): Hamilton Anxiety Rating Scale Interview guide: Joint interview and test-retest methods for interrater reliability. Psychiatry Res 53:191–202.

29. Spielberg CR, Gorsuch RL, Lushe D, Vagg PR, Jacobs GA (1983): Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.

30. Michalopoulou PG, Surguladze S, Morley LA, Giampietro VP, Murray RM, Shergill SS (2008): Facial fear processing and psychotic symptoms in schizophrenia: Functional magnetic resonance imaging study. Br J Psychiatry 192:191–196.

31. Surguladze SA, Etkin A, Kalidindi S, Corsico A, Giampietro V, et al. (2008): Genetic variation in the serotonin transporter modulates neural system-wide response to fearful faces. Genes Brain Behav 7:543–551.

32. Exman P, Friesen W (1975): Pictures of Facial Affect. Palo Alto, CA: Consulting Psychologists Press.

33. Morris JS, Friston KJ, Buché C, Frith CD, Young AW, Calder AJ, Dolan RJ (1998): A neuromodulatory role for the human amygdala in processing emotional facial expressions. Brain 121:47–57.

34. Fu CHY, Williams SCR, Brammer MJ, Suckling J, Kim J, Cleare AJ, et al. (2007): Neural responses to happy facial expressions in major depression following antidepressant treatment. Am J Psychiatry 164:599–607.

35. Fu CHY, Williams SCR, Cleare AJ, Scott J, Mitterschiffthaler MT, Walsh ND, et al. (2008): Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry 64:505–512.

36. Glover GH, Li T-Q, Ressa D (2000): Image-based method for retropective correction of physiological motion effects in fMRI: RETROICOR. Magn Reson Med 44:162–167.

37. Siegel JS, Power JD, Dubis JW, Vogel AC, Church JA, Schlaggar BL, Petersen SE (2014): Statistical improvements in functional magnetic resonance imaging analyses produced by censoring high-motion data points. Hum Brain Mapp 35:1981–1996.

38. Cooney RE, Atlas LY, Joormann J, Eugène F, Gottlib IH (2006): Amygdala activation in the processing of neutral faces in social anxiety disorder: Is neutral really neutral? Psychiatry Res Neuroimaging 148:55–69.

39. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273–289.

40. Hamilton M (1959): The assessment of anxiety states by rating. Br J Med Psychol 32:50–55.

41. Godlewskia BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ (2012): Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol Med 42:2609–2617.

42. Fonzo GA, Ramsawh T, Flagan TM, Sullivan SG, Simmons AN, Paulus MP, Stein MB (2014): Cognitive-behavioral therapy for generalized anxiety disorder is associated with attenuation of limbic activation to threat-related facial emotions. J Affect Disord 169:76–85.

43. Mechias M-L, Etkin A, Kalisch R (2010): A meta-analysis of instructed fear studies: Implications for conscious appraisal of threat. Neuroimage 49:1760–1768.

44. Robinson OJ, Overstreet C, Allen PS, Letkiewicz A, Vytal K, Pine DS, Grillon C (2013): The role of serotonin in the neurocircuity of negative affective bias: Serotonergic modulation of the dorsal medial prefrontal-amygdala “aversive amplification” circuit. Neuroimage 78:217–223.

45. Pidoplichko VI, Prager EM, Aroniadou-Anderjaska V, Braga MFM (2013): z7-Containing nicotinic acetylcholine receptors on interneurons of the basolateral amygdala and their role in the regulation of the network excitability. J Neurophysiol 110:2358–2369.

46. Aragão-Almeida CD, Antunes FD, Barbosa V dos S, Teixeira-Silva F (2016): Are women sensitive to the acute anxiolytic effect of diazepam? J Depress Anxiety 5:1–11.

47. Terner JM, de Wit H (2006): Menstrual cycle phase and responses to drugs of abuse in humans. Drug Alcohol Depend 84:1–13.

48. Donzuso G, Cerasa A, Giola MC, Caracciolo M, Quattrone A (2014): The novel anxiolytic compound BNC210 is a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor. Washington DC: Presented at Neuroscience 2014, November 15, 2014.